GET DAILY SIGNALSWhitehawk Therapeutics (WHWK): What to Expect From the Q3 2026 Earnings Report
Key Takeaways
- Whitehawk Therapeutics (WHWK) is expected to report its third-quarter 2026 results on or around November 11, 2026, before the market open, covering the quarter ended September 30, 2026.
- Consensus estimates point to a net loss of roughly $0.22 to $0.30 per share, with essentially zero product revenue after the divestiture of its FYARRO business.
- Investor attention will center on the company's cash runway and progress toward the Phase 1 trial of its lead next-generation antibody-drug conjugate (ADC) candidate, HWK-206.
- In its most recent quarter, Whitehawk posted a narrower-than-expected loss, a trend shareholders will be watching for again in this report.
- For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Explore Trending AI Robots to discover AI-driven trading strategies and market signals.
Earnings Context and Why It Matters
Whitehawk Therapeutics (WHWK) is a clinical-stage oncology company that has undergone a sharp strategic pivot over the past year. After divesting its only commercial product, FYARRO, to KAKEN Pharmaceutical, the company now generates essentially no product revenue and is focused entirely on advancing a portfolio of next-generation ADCs. Because the income statement no longer reflects meaningful sales, this quarterly report matters less for top-line results and more for operating discipline, cash management, and research and development (R&D) progress. For investors, the print is a key checkpoint on whether Whitehawk remains on track to reach meaningful clinical milestones while preserving a cash runway that management has guided into the second half of 2028.
Earnings Expectations
Heading into the report, Wall Street consensus calls for Whitehawk Therapeutics (WHWK) to post a net loss of roughly $0.22 to $0.30 per share for the third quarter of fiscal 2026. Revenue is expected to be negligible, reflecting the completed sale of the FYARRO franchise. With no commercial product to drive sales, analysts and investors will instead focus on operating expenses, particularly R&D spending, and on the balance of cash and cash equivalents at quarter end. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For historical context, the company reported a loss of $0.20 per share in the second quarter of 2026, a narrower deficit than the roughly $0.31 per share analysts had projected. In the first quarter, it reported a loss of $0.32 per share against a $0.33 consensus estimate. Key metrics to watch this quarter include total operating loss, R&D expense, cash position, and any updated guidance on how long the company's liquidity can fund its development programs.
Market Reaction and Investor Sentiment
Sentiment heading into the report remains cautious. Despite beating consensus estimates in its last release, the stock has drifted lower in the weeks since, with data indicating a negative post-earnings drift following the August announcement. As a pre-revenue clinical-stage company, Whitehawk (WHWK) is highly sensitive to news flow around its pipeline and balance sheet, and the market's focus has shifted toward whether the company can execute on its ADC programs without dilutive financing in the near term. Key risk factors heading into earnings include the pace of R&D spending, any changes to cash-runway guidance, and the timing of the planned Phase 1 trial initiation for HWK-206.
Forward Outlook and Key Factors to Monitor
Following the earnings release, investors will be watching several forward-looking factors closely. The most important near-term catalyst is the initiation of the Phase 1 clinical trial for HWK-206, the company's lead next-generation ADC candidate, which management has indicated is expected to begin during the third quarter of 2026.
Cash management will remain a central theme. After a roughly $87.5 million financing completed in May 2026 lifted cash reserves to about $190 million and extended the operating runway into the second half of 2028, investors will look for confirmation that spending remains aligned with that trajectory. Any meaningful acceleration in R&D or general and administrative expenses could pressure sentiment around the company's funding needs.
Broader industry dynamics also matter. The ADC space continues to attract strong interest from both large pharmaceutical companies and investors, and progress across Whitehawk's (WHWK) three next-generation ADC programs could shape how the market values the pipeline. Finally, investors should monitor any commentary on potential partnerships, additional financing, or strategic updates that management provides alongside the results, as these disclosures often carry more weight than the headline financial figures for a pre-revenue biotech.
My Take on AI-Powered Research Tools
In my own workflow, I frequently rely on Tickeron’s AI Screener to quickly filter clinical-stage biotechs like Whitehawk (WHWK) against peers on metrics such as cash position and pipeline momentum. It helps surface comparable names and technical setups without hours of manual screening, which keeps my focus on the fundamentals that matter most for names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WHWK sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for WHWK moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WHWK as a result. In 71 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WHWK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for WHWK entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where WHWK's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for WHWK just turned positive on October 21, 2026. Looking at past instances where WHWK's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
Following a +10.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where WHWK advanced for three days, in 191 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
WHWK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.941) is normal, around the industry mean (2.904). P/E Ratio (-2.496) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (36.496) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. WHWK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WHWK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement